UNIGE document Scientific Article
previous document  unige:150569  next document
add to browser collection
Title

Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2

Authors
Muench, Peter
Jochum, Simon
Wenderoth, Verena
Ofenloch-Haehnle, Beatus
Hombach, Michael
Strobl, Matthias
Sadlowski, Henrik
Sachse, Christopher
show hidden authors show all authors [1 - 11]
Published in Journal of Clinical Microbiology. 2020, vol. 58, no. 10, p. e01694-20
Abstract The Elecsys Anti-SARS-CoV-2 immunoassay (Roche Diagnostics) was developed to provide accurate, reliable detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated sensitivity, specificity, cross-reactivity, and agreement with a vesicular stomatitis virus-based pseudoneutralization assay for the Elecsys Anti-SARS-CoV-2 immunoassay. Sensitivity and agreement between Elecsys Anti-SARS-CoV-2 immunoassay and pseudoneutralization assay measurements were evaluated using samples from patients with PCR-confirmed SARS-CoV-2 infection, a majority of whom were hospitalized. Specificity was evaluated using samples from routine diagnostic testing/blood donors collected before December 2019 and thus deemed negative for SARS-CoV-2-specific antibodies. Cross-reactivity was evaluated using samples containing a wide range of potentially cross-reacting analytes, purchased from commercial vendors. For sensitivity and specificity, point estimates and 95% confidence intervals (CIs) were calculated. Agreement between the Elecsys Anti-SARS-CoV-2 immunoassay and the pseudoneutralization assay was calculated. The sensitivity of the Elecsys Anti-SARS-CoV-2 immunoassay in patients with prior PCR-confirmed SARS-CoV-2 infection was 99.5% (95% CI, 97.0 to 100.0%) at ≥14 days post-PCR confirmation. Overall specificity (n = 10,453) was 99.80% (95% CI, 99.69 to 99.88%). Only 4/792 samples containing potential cross-reacting analytes were reactive with the Elecsys Anti-SARS-CoV-2 immunoassay, resulting in an overall specificity in this cohort of 99.5% (95% CI, 98.6 to 99.9%). Positive, negative, and overall agreement (n = 46) between the Elecsys Anti-SARS-CoV-2 immunoassay and the pseudoneutralization assay were 86.4% (95% CI, 73.3 to 93.6%), 100% (95% CI, 34.2 to 100%), and 87.0% (95% CI, 74.3 to 93.9%), respectively. The Elecsys Anti-SARS-CoV-2 immunoassay demonstrated high sensitivity (99.5% at ≥14 days post-PCR confirmation) and specificity (99.80%), supporting its use as a tool for identification of past SARS-CoV-2 infection, including use in populations with low disease prevalence.
Keywords Antibodies, Viral/bloodBetacoronavirus/immunology/isolation & purificationCOVID-19 TestingClinical Laboratory TechniquesCoronavirus Infections/blood/diagnosis/epidemiologyCross ReactionsHumansImmunoassayReproducibility of ResultsSARS-CoV-2Sensitivity and Specificity
Identifiers
PMID: 32747400
Full text
Structures
Research group Emerging viruses (993)
Citation
(ISO format)
MUENCH, Peter et al. Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2. In: Journal of Clinical Microbiology, 2020, vol. 58, n° 10, p. e01694-20. doi: 10.1128/JCM.01694-20 https://archive-ouverte.unige.ch/unige:150569

129 hits

11 downloads

Update

Deposited on : 2021-03-22

Export document
Format :
Citation style :